BioCentury | Jul 29, 2020
Emerging Company Profile

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

Bright Peak thinks its medicinal chemistry approach to protein design will make its synthetic cytokines stand out from the pack. Built by Versant Ventures’ Basel-based Ridgeline outpost with technology licensed from ETH Zurich, Bright Peak...
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

Priority Review for Aurinia’s lupus nephritis therapy  FDA accepted and granted Priority Review to an NDA for voclosporin from Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) to treat lupus nephritis. The PDUFA date for the immune-suppressing, IL-2-blocking...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

BioNTech prices upsized financing BioNTech SE (NASDAQ:BNTX) raised $511.5 million in an upsized offering through the sale of 5.5 million ADSs at $93 per ADS. The deal, which had been slated for 5 million ADSs,...
BioCentury | Jul 3, 2020
Deals

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

Novartis to pay $678M in kickbacks settlement  Novartis AG (NYSE:NVS; SIX:NOVN) will pay $678 million and, under a corporate integrity agreement, conduct its speaker programs virtually for the next five years after the pharma reached...
BioCentury | Jun 30, 2020
Finance

June 29 Quick Takes: BioNTech pockets $250M; plus three biotechs join NASDAQ IPO queue

Temasek takes stake in BioNTech   BioNTech SE (NASDAQ:BNTX) raised about $250 million from Temasek and other undisclosed investors in a private placement comprising $139 million in stock and $112 million in convertible notes. The...
BioCentury | Jun 25, 2020
Emerging Company Profile

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

Simcha emerged Wednesday with $25 million in series A funding to bring its lead product, a variant of IL-18 designed to thwart a resistance mechanism in tumors, through Phase I testing. The corporate venture fund...
BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

More than 16 years and five product launches after closing its first deal with Regeneron, Sanofi has sold its holding of roughly 20% of the biotech's shares for about $11.1 billion. While the French pharma...
BioCentury | Apr 27, 2020
Finance

ADC renews IPO bid as first regulatory filing looms

Less than four months after new pivotal data strengthened its case for a BLA submission this year, ADC has again filed a prospectus for an IPO -- although it may be a more modest one...
BioCentury | Apr 1, 2020
Finance

Pandion’s immune-regulating platform attracts $80M B round

Pandion raised $80 million in a series B round, triggered by a pancreas-focused partnership with Astellas and the clinical debut of its lead immune modulator. The modularity attracted Access Biotechnology to co-lead the round with...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

Xilio plans to bring its two lead immuno-oncology candidates to clinical proof-of-concept data, as well as advance its earlier stage programs, with a tranched $100.5 million series B. Takeda Ventures Inc. led the financing with...
Items per page:
1 - 10 of 1232